How to Design a Monitoring Protocol

Structure ongoing lab testing, symptom tracking, and dose adjustments throughout a peptide protocol—organized by compound class with specific monitoring schedules.

Why Monitoring Is the Difference Between Medicine and Gambling

Starting a peptide protocol without a monitoring plan is running an experiment without measuring outcomes. You can feel good and be in trouble. You can feel bad and actually be fine. You can feel nothing and still be creating long-term problems. The only way to know what’s actually happening is to measure it.

Monitoring serves two distinct purposes. First: safety. Blood work catches problems before symptoms do. Supraphysiological IGF-1 doesn’t announce itself as a feeling—it announces itself as a lab value. Rising fasting glucose on a GH secretagogue is data, not a headache you pushed through. Liver stress from hepatotoxic compounds shows up in liver enzymes before you feel jaundiced. Second: efficacy. You need to know if the protocol is actually working. Not how it makes you feel. Whether it’s producing the biochemical change you’re trying to produce.

The most irresponsible prescribing pattern in peptide medicine is straightforward: write the prescription, never mention labs, never follow up, refill when asked. This is not medicine. This is retail.

A monitoring protocol should be established before the first dose, not improvised later. Your provider should hand you a written schedule showing which labs at which intervals, what targets you’re aiming for, and what findings would prompt a dose adjustment or protocol change. If they don’t have this in writing—if they’re making it up as you go—that tells you something important about the level of care you’re receiving.

The Three Components of a Monitoring Protocol

Every monitoring protocol has three components. All three are necessary. Missing any one makes the system incomplete.

Laboratory Testing

Scheduled blood draws at defined intervals. The specific labs depend on the compound class, but the principle is constant: you need baseline values before starting, checkpoints during the protocol to verify the drug is doing what you expect, and ongoing surveillance to catch problems. This isn’t guesswork. A GH secretagogue protocol that doesn’t check IGF-1 at 6–8 weeks isn’t monitoring—it’s hoping.

Symptom Tracking

Structured self-reporting of both desired and adverse effects. Your subjective experience matters, but it’s not data by itself. A symptom tracking log quantifies that experience. It lets you spot trends (your sleep improved week one through six, then declined, which suggests dose adjustment), and it gives your provider actual information instead of how you felt on the day of your appointment.

Dose Adjustment Criteria

Predefined rules for when and how to change the protocol. This is the critical piece most people skip. “I’ll adjust based on how I feel” is not criteria—it’s the opposite. Criteria are specific: if IGF-1 exceeds 300 ng/mL, reduce dose by 25%. If fasting glucose rises more than 15 mg/dL from baseline, reassess the protocol. If carpal tunnel symptoms persist for more than two weeks, stop and evaluate. Written in advance, criteria prevent arbitrary decisions.

All three are required. Labs without symptom context miss the human experience—you might have perfect lab values and feel terrible, which matters. Symptoms without labs are guesses—you can’t know if your fatigue is from the protocol or from sleep debt without data. Adjustments without criteria are arbitrary—”I’m going to increase the dose” becomes a dice roll instead of a decision.

GH Secretagogue Monitoring Protocol

Compounds: CJC-1295 (no DAC), CJC-1295 (with DAC), ipamorelin, sermorelin, tesamorelin, hexarelin, GHRP-2, GHRP-6, MK-677 (not a peptide).

Baseline Labs (Before First Dose)

• IGF-1
• IGFBP-3 (insulin-like growth factor binding protein-3)
• Fasting glucose
• Fasting insulin
• HbA1c
• Comprehensive Metabolic Panel (CMP)
• Complete Blood Count (CBC)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)

6–8 Weeks (Early Response Check)

• IGF-1 (critical—this is your primary safety marker)
• Fasting glucose
• Fasting insulin

The 6–8 week checkpoint is non-negotiable. GH secretagogues take 4–6 weeks to reach steady-state IGF-1 elevation. By week 6–8, you have real data on how much IGF-1 is rising. This is the critical point to catch dose-related problems. If IGF-1 is already supraphysiological, you adjust now, not at 12 weeks.

12 Weeks (Full Panel Recheck)

• IGF-1
• Fasting glucose
• Fasting insulin
• HbA1c
• CMP

Ongoing (Every 3–6 Months)

• IGF-1 (minimum)
• Fasting glucose
• HbA1c

For long-term protocols (beyond 6 months), add CMP annually to monitor organ function and lipid panel annually.

IGF-1 Target Range

Upper-normal for age is the rational target. Normal IGF-1 ranges vary by age: roughly 125–200 ng/mL in adults 30–40, declining thereafter. Your goal is to push IGF-1 into the upper portion of the normal range for your age, not beyond it. Supraphysiological levels—consistently exceeding 300 ng/mL in most adults—should trigger dose reduction. There is no benefit to IGF-1 above 300; there is risk.

Glucose Monitoring: The Expected Response

GH secretagogues raise fasting glucose. This is expected. Growth hormone antagonizes insulin action—it’s part of the pharmacology. Small elevations of 5–10 mg/dL are normal and typically not concerning. Your fasting glucose of 95 mg/dL rising to 100–105 mg/dL is not an indication to stop; it’s an indication to monitor.

Significant elevations—say, 20–30 mg/dL increases—warrant protocol review. If your fasting glucose was 90 mg/dL and is now 120 mg/dL, the dose is probably too high, or you’re metabolically sensitive to GH elevation. HbA1c at 12 weeks tells you if glucose elevation is meaningful or transient. A rising HbA1c suggests the protocol is genuinely raising your glucose metabolism; a stable HbA1c despite elevated fasting glucose is less concerning.

MK-677 Specifically

MK-677 (not a peptide—it’s a small-molecule GH secretagogue) produces continuous, not pulsatile, GH elevation. This matters for glucose: multi-year clinical trials show documented fasting glucose increases that are more pronounced than pulsatile GH secretagogues. If you’re using MK-677 and see a 15–20 mg/dL glucose rise, that’s on-target pharmacology. This doesn’t mean you ignore it—you still monitor HbA1c—but it’s expected, not surprising.

Prolactin Monitoring

If using GHRP-2 or GHRP-6, add prolactin at baseline and 12 weeks. These compounds elevate prolactin more than ipamorelin does. Chronically elevated prolactin can cause galactorrhea, sexual dysfunction, and mood changes. Ipamorelin and CJC-1295 (no DAC) elevate prolactin minimally—routine prolactin monitoring isn’t necessary with these compounds.

Symptoms to Track

• Sleep quality. GH is released primarily during sleep. Many report sleep improvement on GH secretagogues. Track 1–10 scale or hours slept. Dramatic sleep improvement is encouraging signal; sleep deterioration at higher doses is a warning sign.
• Water retention. GH promotes water retention. Mild puffiness is expected and usually benign. Significant swelling—pitting edema, tight rings, weight gain from fluid not fat—warrants dose reduction.
• Joint pain or stiffness. Can be a sign of excessive GH. If you develop new joint complaints on protocol, track location and severity. Pain that worsens with time on drug is concerning; pain that improves is not.
• Carpal tunnel symptoms. GH can cause carpal tunnel or worsen existing carpal tunnel. Numbness or tingling in thumb, index, and middle fingers—especially at night—is specific. This is a dose-reduction trigger, not a “try to push through it” symptom.
• Appetite changes. Most notice appetite increase, which is normal GH physiology. Loss of appetite on GH secretagogues is atypical and warrants investigation.

When to Stop or Reduce Dose

• IGF-1 persistently supraphysiological (>300 ng/mL in most adults)
• Significant fasting glucose elevation (>20–25 mg/dL from baseline) with rising HbA1c
• Persistent edema that doesn’t improve with dose reduction within 2 weeks
• Carpal tunnel symptoms that limit function

Dose reduction happens before you’ve convinced yourself to stop entirely. If carpal tunnel symptoms appear at 100 mcg, drop to 75 mcg. Wait two weeks. Reassess. This is medicine—it’s iterative, not binary.

GLP-1 Medication Monitoring Protocol

Compounds: semaglutide, tirzepatide, liraglutide (and experimental compounds like retatrutide).

Baseline Labs (Before First Dose)

• HbA1c (critical for baseline glucose control)
• Fasting glucose
• Fasting insulin
• Lipid panel
• Comprehensive Metabolic Panel (liver and kidney function)
• Amylase and lipase (pancreatic function baseline)
• Thyroid panel (TSH, Free T4) — not required universally, but prudent if you have thyroid history
• Body weight and body composition if possible (DEXA or bioimpedance)

4–6 Weeks (Each Dose Titration)

GLP-1 medications are dosed in steps. Most protocols begin low and increase every 4 weeks until reaching maintenance dose. At each titration step, schedule a symptom check—not labs, but a conversation with your provider about GI tolerance, appetite suppression, energy, and mood. Are you holding well at this dose, or is it already too high? This information guides the next step.

• Nausea, vomiting, diarrhea, constipation (assess severity and timeline)
• Appetite suppression (is it appropriate or excessive?)
• Energy levels
• Any new symptoms (flushing, dizziness, etc.)

12 Weeks (Once at Maintenance Dose)

• HbA1c
• Fasting glucose
• Lipid panel
• CMP (reassess kidney function, liver function)
• Body weight

Ongoing (Every 3–6 Months)

• HbA1c
• Lipid panel
• Kidney function (creatinine, eGFR)
• Body weight

GLP-1 Symptoms: What’s Tolerable and What Isn’t

GLP-1 agonists are dose-limited by GI effects. Nausea, vomiting, diarrhea, and constipation occur in 10–20% of people at meaningful doses. This is pharmacology, not toxicity—but it’s also why you don’t just push the dose higher.

Mild nausea for a few days after titration up, then resolution, is expected. Persistent nausea that hasn’t improved after 2–3 weeks at the same dose is your signal to either stay put or reduce. You’re not being weak; you’re recognizing that further titration won’t work for you at this time.

Appetite suppression is the mechanism—you want this—but excessive appetite suppression (you can’t eat enough to meet protein targets) is a dose problem. You’re aiming for “I’m satisfied with less food,” not “I can barely eat.”

The Hair Loss Question

Rapid weight loss—any weight loss, but especially rapid—can trigger or worsen telogen effluvium (diffuse hair shedding). This is usually temporary and resolves as weight stabilizes, but it’s real. If you notice increased hair shedding 2–4 months into protocol, this is likely the mechanism. It will resolve, but you need to know it’s coming and not panic.

Gallbladder Concerns

Rapid weight loss increases gallstone formation risk. GLP-1 agonists also slow gastric emptying, which may increase gallbladder disease risk as a secondary mechanism. The classic presentation is right upper quadrant pain, especially after meals, sometimes radiating to the back or shoulder. If you develop this, stop the medication and seek immediate evaluation. This is not a “continue and monitor” situation.

The Muscle Mass Concern

Weight loss on GLP-1 agonists includes both fat and lean mass. The lean mass loss isn’t from the drug directly—it’s from caloric deficit. But the pharmacological appetite suppression makes it easier to undereat relative to your protein needs. The countermeasures are straightforward: (1) protein intake of at least 1 g/kg/day, ideally closer to 1.2–1.6 g/kg/day on caloric deficit; (2) resistance training 3–4 times per week; (3) body composition monitoring (DEXA or bioimpedance every 12 weeks) to verify you’re losing fat, not muscle.

If you’re on a GLP-1 agonist and under-eating protein, you will lose muscle. This is not the drug’s fault—it’s your protocol design. Fix it in advance.

When to Reduce Dose

• Persistent nausea that hasn’t improved after 2–3 weeks at current dose
• Significant GI distress (vomiting, severe diarrhea) that limits daily function

When to Stop and Seek Evaluation

• Severe abdominal pain radiating to back (pancreatitis concern)
• Persistent vomiting with inability to keep down fluids
• Right upper quadrant pain (gallbladder concern)
• Sudden change in stool color or appearance (possible liver or biliary obstruction)

These are not dose-reduction situations. These are “stop immediately and call your provider” situations.

Sexual Health / Hormonal Peptide Monitoring

Compounds: PT-141 (bremelanotide), gonadorelin, kisspeptin.

PT-141 (Bremelanotide)

PT-141 is a melanocortin receptor agonist. Blood pressure check before use and during initial doses is mandatory. This compound raises blood pressure in most people. Baseline blood pressure, then recheck within the first week of use, then every 2–4 weeks if continuing.

PT-141 is approved (as Vyleesi) for premenopausal HSDD (hypoactive sexual desire disorder) and is intended for single-dose PRN (as-needed) use, not daily or chronic protocols. Community use has extended beyond this approved indication into chronic dosing, which has no clinical data support. If you’re using PT-141 chronically (more than weekly), you’re in territory with no monitoring standard. Keep baseline and periodic blood pressure, monitor for sustained hypertension, flushing reactions, or mood changes.

PT-141 flushing (skin reddening, warmth) is common and usually benign but annoying. Flushing that intensifies or doesn’t resolve suggests dose is too high.

Gonadorelin and Kisspeptin

Gonadorelin is a GnRH (gonadotropin-releasing hormone) agonist—it stimulates the pituitary to release LH and FSH, which in turn stimulate testosterone or estrogen production. The purpose is to restore endogenous hormone production.

Kisspeptin is an upstream controller of GnRH—it’s even more upstream in the axis than gonadorelin. Clinical data is extremely limited for exogenous kisspeptin use.

For both: baseline LH, FSH, testosterone (if male), estrogen markers (if female), then recheck at 4–6 weeks. The question you’re answering: is the peptide working? Are LH and FSH rising (indicating the pituitary is responding), and is peripheral hormone rising (testosterone, estrogen) as a result? If neither is happening, the peptide isn’t working, and the protocol needs revision.

Symptoms to monitor: sexual function (the actual endpoint—is it improving?), mood, acne or skin changes, energy, any unexpected symptoms. Gonadorelin and kisspeptin don’t typically cause dramatic adverse effects, but mood swings or energy crashes should prompt a hormonal recheck.

Both gonadorelin and kisspeptin lack the extensive clinical monitoring data that comes with FDA-approved endocrine medications. Work with a provider experienced with these compounds, and don’t assume that “it’s natural/endogenous” means “it’s automatically safe.” Monitoring is more important precisely because the data is sparse.

Tissue Repair / Recovery Peptide Monitoring

Compounds: BPC-157, TB-500.

Here’s the honest caveat: there are no established clinical monitoring protocols for these compounds because there are no completed clinical trials that define monitoring standards. BPC-157 has three human studies; TB-500 has zero. This doesn’t mean these peptides are useless—the animal data is compelling—but it does mean we’re in exploratory territory, and your monitoring protocol has to be thoughtful precisely because the evidence base is thin.

Baseline Labs (Reasonable)

• CMP (comprehensive metabolic panel—liver function specifically, since BPC-157 has some hepatic metabolism)
• CBC (complete blood count)
• Inflammatory markers (hsCRP, ESR) — not required but reasonable if you’re using these for tissue repair related to inflammation

4–6 Week Follow-up

• CMP (verify liver function remains stable)

Symptoms and Functional Outcomes

The primary monitoring metric is the condition you’re treating: Is the injury/condition improving? Track the specific outcome: pain scale for a rotator cuff injury, ROM (range of motion) for a joint, healing progress for a wound, function for a GI issue, etc. Keep a simple log.

Track for general adverse effects: any GI symptoms (BPC-157 is administered systemically in some protocols and can affect GI function), rashes, unusual symptoms.

Protocol Duration and Exit Strategy

Most community protocols run 4–8 weeks. There is no clinical data on long-term use—no one has run a multi-year study. An open-ended protocol (“I’ll just keep injecting until I feel like stopping”) without monitoring is not advisable. Define in advance: I will run BPC-157 for 6 weeks, reassess at 6 weeks based on functional improvement, then either stop or extend for 4 more weeks with a repeat CMP at week 10.

This structure gives you clear decision points. It also prevents the drift into indefinite protocols with no endpoint and minimal monitoring.

BPC-157 and TB-500 are not vaccines or vitamins—they’re active pharmacological interventions with sparse human data. Respect that fact in your monitoring design.

Building a Symptom Tracking System

Symptom tracking doesn’t require apps or elaborate systems. A spreadsheet works. A notebook works. The point is to quantify what you’re experiencing so it becomes data instead of feelings about a single day.

Daily Log: What to Track

Set up a spreadsheet with these columns:

• Date
• Sleep Quality: 1–10 scale (1 = couldn’t sleep, 10 = perfect sleep)
• Energy: 1–10 scale
• Compound-Specific Symptoms: For GH secretagogues, track water retention (mild/moderate/severe), joint pain (location + severity). For GLP-1, track nausea (0–10), appetite (satisfied normally / barely hungry / ravenous), stool consistency. For PT-141, track blood pressure if you have a home monitor, flushing severity.
• Unexpected Symptoms: Any rashes, headaches, mood changes, etc.
• Weight (if tracking—weigh yourself same time, same conditions, no more than once daily)
• Notes: Anything relevant. “Carpal tunnel worse today.” “Slept 11 hours.” “Nausea much better after dose reduction.”

Weekly Review

Once a week (Sunday evening, or whenever you choose), review the past 7 days. Don’t look at individual days. Look for trends: Did sleep improve week 1–3, then decline week 4–5? That’s signal. Did energy crash this week? That’s signal. Did nausea gradually improve or stay the same? The trend matters; the individual day doesn’t.

Sharing With Your Provider

Print or screenshot the spreadsheet for your check-in appointments. This is data. Your provider now has quantified information—”sleep improved 2 points on 1–10 scale” instead of “I’m sleeping better.” This is how monitoring conversations should go: review trend data, review lab results, adjust protocol accordingly.

You can also use simple tracking apps (Apple Health, Cronometer, even Google Sheets), but the principle is the same: quantify, identify trends, share with provider.

Dose Adjustment Decision Framework

Never adjust doses based on a single lab result or a single day of symptoms. A single number is noise. Trends are signal. One carpal tunnel day doesn’t mean reduce dose; carpal tunnel every day for two weeks means reduce dose.

The Three-Question Framework

When considering a dose adjustment, ask in order:

1. Is the protocol safe? Are the lab markers acceptable? Is anything concerning emerging? If labs show supraphysiological IGF-1, elevated liver enzymes, or significant glucose elevation, the answer is “no,” and you adjust down or stop.
2. Is it effective? Are you getting the desired outcome? If you’re on a GH secretagogue and seeing zero sleep improvement at week 8, and symptoms are flat, it’s not effective. If you’re on GLP-1 and your weight hasn’t budged, it’s not working at this dose.
3. Is the dose appropriate? Not too much, not too little? Once you’ve confirmed safety and efficacy, you optimize dose. Too low—no effect. Too high—side effects outweigh benefit.

Direction of Adjustment

Adjusting UP: Only after confirming safety markers are acceptable AND efficacy is suboptimal. You’ve verified lab safety, symptom benefit is minimal, and the protocol tolerates higher dose. Then you increase.

Adjusting DOWN: Immediately if safety markers are concerning. Don’t wait for the next scheduled check. A lab showing supraphysiological IGF-1 at 6 weeks means you reduce dose now, not “let’s see what happens by 12 weeks.” Persistent adverse symptoms (carpal tunnel, severe nausea) that don’t improve within 2 weeks also warrant dose reduction.

Rule: Safety > Efficacy. Always. A protocol that feels great but produces supraphysiological IGF-1 is unsafe and must be adjusted. A protocol that’s safe but feels mediocre is tolerable and can be optimized. But unsafe protocols can’t be justified by subjective benefit.

Stopping the Protocol: Exit Criteria

Define exit criteria before you start. Examples:

• “I will run GH secretagogues for 12 weeks. At 12 weeks, if IGF-1 is normal and sleep has improved ≥2 points, I will reassess and consider continuing. If sleep improvement is <1 point, I will stop."
• “I will run GLP-1 for 16 weeks (4 weeks to reach dose + 12 weeks at maintenance). If weight loss is <5 lbs, I will stop. If weight loss is ≥5 lbs and side effects are tolerable, I will reassess and consider extending."
• “I will run BPC-157 for 6 weeks. At 6 weeks, I will assess shoulder ROM (range of motion) and pain. If ROM improved ≥20% and pain reduced ≥3 points on 10-point scale, I will consider 4 more weeks. If neither changed, I will stop.”

This prevents drift. You’re not running a “forever protocol” with no endpoint. You’re running an experiment with a defined hypothesis, duration, and success criteria. At the end, you evaluate based on those criteria, not on how you feel that day.

Working With Your Provider on Monitoring

Your provider should initiate monitoring. They should hand you a written schedule before you start: baseline labs on this date, follow-up labs on these dates, what findings will trigger dose changes. If you’re left to initiate your own monitoring because your provider hasn’t, that’s a yellow flag about the quality of care you’re receiving. Reconsidering the provider is reasonable.

How to Share Self-Ordered Lab Results With Telehealth Providers

If you’re using a DTC (direct-to-consumer) lab company to get your own blood work, follow this approach with your provider:

1. Order labs through the DTC company (Ulta Lab Tests, LabCorp, Quest, WellnessFX, etc.)
2. Once results are available, download the PDF report
3. Share the report with your provider via secure portal or email (ask which method they prefer)
4. Schedule a telehealth visit to discuss: review the results, symptom log, adjust protocol if needed, schedule next labs

Most reputable telehealth providers will accept outside lab results. Some will require their own lab orders (which they can usually waive the cost for if you’ve already done testing). A few bad actors will only accept results from “approved” labs—a sign of captive care designed to increase their revenue, not improve your outcomes. Avoid those.

What a Good Monitoring Conversation Looks Like

Provider: “Let’s review your labs. IGF-1 was 95 at baseline, now 265 at 8 weeks. That’s good—upper-normal range. Fasting glucose went from 92 to 102. That’s expected on GH secretagogues. HbA1c should stay normal. Let’s recheck at 12 weeks. How are you feeling?”

You: “Sleep is better, up about 2 points on the scale. No carpal tunnel yet. A little more water retention in my face.”

Provider: “Good. That matches the labs—you’re seeing benefit without excess. Let’s stay at this dose, recheck IGF-1 and glucose at 12 weeks, and we’ll see where we are. If anything changes—new symptoms, dramatic weight changes, anything unexpected—text me.”

This conversation is 5 minutes. It integrates labs, symptoms, and clear next steps. This is medicine.

What a Bad Monitoring Conversation Looks Like

Provider: “Everything fine? Good, refill sent.”

Or worse: they don’t ask for follow-up labs at all. “Just call me if anything weird happens.”

This is not monitoring. This is retail. Labs matter. Symptom trends matter. Regular reassessment matters. If your provider isn’t doing this, find one who will.

Cross-Reference: Finding the Right Provider

See What to Look for in a Peptide Telehealth Provider for specific guidance on provider vetting, credentials, and red flags.

Frequently Asked Questions

[FAQ section will be populated by Rank Math—questions and answers follow in separate text file]